Literature DB >> 9426398

Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.

H M Sowter1, A N Corps, A L Evans, D E Clark, D S Charnock-Jones, S K Smith.   

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic factor secreted by various tumors, including epithelial tumors of the ovary, and is involved in tumor progression and maintenance. The significance and function of other members of the VEGF family in the ovary has not yet been elucidated. In the present study, we have defined the expression of mRNA encoding VEGF-B, VEGF-C, and placenta growth factor (PIGF), compared with that of VEGF mRNA, in normal ovary and a range of ovarian epithelial tumors. Analysis by reverse transcription-PCR indicated that mRNA encoding VEGF (isoforms 121 and 165), VEGF-B (isoforms 167 and 186), and VEGF-C, but not PIGF, were present in all ovarian tissues examined. By in situ hybridization, neither VEGF-C nor PIGF transcripts were detected in any of the samples. The expression pattern of VEGF-B mRNA was generally similar to that of VEGF mRNA, in that transcripts were readily detected in the epithelial cells of all histologic types of ovarian carcinoma, but could not be detected in normal or benign tumor epithelium. Specific differences in the expression of the two genes were noted in areas of tumor necrosis, in which the expression of VEGF mRNA, but not VEGF-B mRNA, was further enhanced, and in a sample in which VEGF-B mRNA was strongly expressed in tumor-associated macrophages that did not hybridize with the riboprobe to VEGF mRNA. These results imply that a second member of the VEGF family, VEGF-B, may play a significant role in the angiogenesis, progression, and maintenance of ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426398

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

Authors:  R F Nicosia
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

3.  Enhancement by histamine of vascular endothelial growth factor production in granulation tissue via H(2) receptors.

Authors:  A K Ghosh; N Hirasawa; K Ohuchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors.

Authors:  T Minko; P Kopeckova; V Pozharov; K D Jensen; J Kopecek
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

5.  VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.

Authors:  Alexander Schultze; Isabel Ben Batalla; Sabine Riethdorf; Michael Bubenheim; Emre Yekebas; Andreas Erbersdobler; Uta Reichelt; Katharina E Effenberger; Thomas Schmidt; Jakob R Izbicki; Carsten Bokemeyer; Klaus Pantel; Walter Fiedler; Sonja Loges
Journal:  Clin Exp Metastasis       Date:  2012-04-08       Impact factor: 5.150

Review 6.  Vascular endothelial growth factor in ovarian cancer.

Authors:  D A Hazelton; T C Hamilton
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

7.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

8.  A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.

Authors:  Andrea Vecchione; Barbara Belletti; Francesca Lovat; Stefano Volinia; Gennaro Chiappetta; Simona Giglio; Maura Sonego; Roberto Cirombella; Elisa Concetta Onesti; Patrizia Pellegrini; Daniela Califano; Sandro Pignata; Simona Losito; Vincenzo Canzonieri; Roberto Sorio; Hansjuerg Alder; Dorothee Wernicke; Antonella Stoppacciaro; Gustavo Baldassarre; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-22       Impact factor: 11.205

9.  Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.

Authors:  M A Ghanem; G J van Steenbrugge; M K Sudaryo; R B Mathoera; J M Nijman; Th H van der Kwast
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

10.  Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference.

Authors:  Shaochuang Wang; Hui Liu; Lifeng Ren; Yifeng Pan; Yangde Zhang
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.